Josh Bilenker and Jeff Engelman bundle a mother lode of cash for their stealthy startup, attracting a who's who of biotech investors
Josh Bilenker and Jeff Engelman won’t be worrying about money for their stealthy startup anytime soon.
Late last week the pair filed a Form D for their new biotech Treeline Biosciences outlining a $212 million raise for their new company — which Bilenker founded around the time he ejected from his top position at Eli Lilly’s oncology group.
Their plan is to top out the raise at $220 million, but with Bilenker’s list of marquee investors on board for his latest creation, that won’t be much of a stretch.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.